Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonsurf drug-drug interaction study with metformin and cimetidine in metastatic cancer
NL-OMON54985Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil, metformin and cimetidine in gastrointestinal cancer, colorectal cancer (CRC) and gastric cancer (GC), sponsored by Erasmus MC. Primary endpoints: Effect of metformin on Lonsurf exposure and Effect of cimetidine on Lonsurf exposure. Started Oct 2019; status: completed.
02
Drugs
trifluridine + tipiracilmetformincimetidine
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON54985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54985.